Aventis Pharma today said it expects to launch a prostate cancer drug by next year for which it is currently in the process of getting approval from the drug regulator DCGI.
The company also said nearly half of its 15 to 20 molecules in the pipeline have reached the third phase of development.
"We are planning to launch a prostate cancer drug, Cabazitaxel by next year," Aventis Pharma Director, Clinical Research, Mubarak Naqvi said on the sidelines of a CII function here.
He said that the company has already received approval from the USFDA for the drug.
"It (the drug) is under process to gain approval from the Drug Controller General of India (DCGI) for the launch in India and we hope to get it soon," Naqvi said.
Commenting on the company's other molecules in the pipeline, he said that it has about 15-20 molecules under development.
"0ut of them half are in the third stage of development and these could be for therapeutic areas like diabetes, thrombosis and other types of cancer besides cardiovascular diseases," he added.
The company's shares were trading at Rs 1,837 per share at the Bombay Stock Exchange, down 0.70 per cent in afternoon trade.
